Skip to main
CLB
CLB logo

CLB Stock Forecast & Price Target

CLB Analyst Ratings

Based on 29 analyst ratings
Buy
Strong Buy 31%
Buy 14%
Hold 45%
Sell 10%
Strong Sell 0%

Bulls say

Core Laboratories is demonstrating strong financials with consistent year-on-year (YoY) growth in RD revenue and a substantial increase in free cash flow, rising from negative in Q3 2023 to positive $16.7 million. The company showcases improved fiscal management, as indicated by the lowered leverage ratio from 1.92x to 1.76x. Furthermore, the firm's Production Enhancement segment is anticipated to benefit from the rising U.S demand and the firm's RD revenue has historically successfully outpaced changes in the international rig count, indicating resilience and strong revenue generation capacity.

Bears say

Core Laboratories is facing negative growth in recent years (2017-19 and 2022), despite overall industry activity, especially in its Reservoir Description segment, leading to under-performance in RD revenue growth. The company's adjusted operating income dropped to $15.0 million recently from $16.0 million in the third quarter of 2023, and it anticipates a 2.5% sequential decrease in 1Q24 revenue ($122.0-128.0 million), which if fails to materialize could be a further detraction to the stock. Moreover, the potential risks including a significant drop in oil prices and a slower recovery in the U.S exacerbate the company's already weak financial position.

CLB has been analyzed by 29 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 14% recommend Buy, 45% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Core Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Core Laboratories Inc (CLB) Forecast

Analysts have given CLB a Buy based on their latest research and market trends.

According to 29 analysts, CLB has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.61, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.61, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Core Laboratories Inc (CLB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.